+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030- Product Image
Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030- Product Image
Sale

Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674204
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neutropenia treatment market is evolving swiftly through scientific innovation, competitive pressures, and regionally diverse demands. Senior decision-makers navigating this market require a comprehensive view of its segmentation, strategic drivers, and emerging opportunities to inform forward-looking decisions and sustain growth as the healthcare landscape changes.

Market Snapshot: Neutropenia Treatment Market

The neutropenia treatment market grew from USD 15.08 billion in 2024 to USD 15.85 billion in 2025 and is expected to progress at a CAGR of 5.02%, reaching USD 20.24 billion by 2030. This growth is grounded in robust demand for advanced therapies, regulatory momentum, and heightened focus on tailored care solutions across oncological and infectious disease care pathways.

Scope & Segmentation

This analysis holistically covers the global scope of neutropenia care, mapping pivotal segments and strategic dimensions:

  • Treatment Types: Filgrastim (available in 300 mcg, 480 mcg, 600 mcg), Lenograstim (3 mg, 5 mg), Pegfilgrastim (6 mg).
  • Therapy Class: Differentiates biosimilar products versus originators.
  • Route of Administration: Intravenous and subcutaneous injection methods, each impacting workflow and patient experience.
  • Distribution Channels: Encompasses hospital pharmacies (inpatient, outpatient), online pharmacies, chain retail pharmacies, and independent pharmacies.
  • End Users: Categories include ambulatory care centers, clinics, home care settings, and hospitals (split into private and public sectors).
  • Patient Age Groups: Adult, geriatric, pediatric populations drive differing adoption and safety considerations.
  • Severity Levels: Classifies patient needs as mild, moderate, or severe, shaping clinical approaches.
  • Geographies Covered: Scope spans Americas (United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including Germany, France, UK, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, and others); Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia, and more).
  • Leading Companies: Detailed coverage includes Amgen Inc., Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Coherus BioSciences, Inc., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Biocon Limited, Celltrion, Inc.

Key Takeaways for Senior Decision-Makers

  • Rapid shifts in care models are influencing the design, adoption, and differentiation of neutropenia treatments, with biosimilar options challenging traditional therapies.
  • Patient-centric trends, especially advances in remote monitoring and digital adherence tools, are streamlining care delivery and providing competitive advantages for market leaders who adopt them.
  • Regulatory frameworks are evolving, with adaptive pathways increasingly supporting expedited product introductions while maintaining stringent safety standards.
  • Segmentation by administration route and dose provides significant opportunities for customized, high-value offerings aligned with stakeholder and patient needs.
  • Strategic collaboration among payers, providers, and manufacturers supports innovative reimbursement models, encouraging sustainable growth and value-based care arrangements.
  • Region-specific strategies remain critical, as differences in healthcare infrastructure, reimbursement, and regulatory processes directly shape market access and uptake.

2025 US Tariff Impact on the Neutropenia Treatment Market

The new tariff structure introduced in early 2025 in the United States has reconfigured cost dynamics across the neutropenia treatment landscape. Manufacturers experience increased import duties on active pharmaceutical ingredients and finished biologics, leading to recalibrated pricing and supply chain strategies. Both contract renegotiations and localized production efforts are mitigating ongoing risks. Downstream, payers and distributors are shifting to value-based reimbursement and collaborative cost management, while biosimilars strengthen their competitive position through enhanced affordability in the evolving tariff environment.

Methodology & Data Sources

This market intelligence builds on primary research—interviews with industry leaders, clinicians, payers, and other stakeholders—supplemented by secondary sources such as regulatory filings, academic literature, corporate presentations, and recognized healthcare databases. Rigorous qualitative analysis and triangulation underpin the findings, with a focus on transparency and cross-validation.

Why This Report Matters

Senior leaders gain actionable insight into a complex, segmented market through this report’s executive guidance:

  • Enables informed investment and portfolio optimization by mapping critical geographic, therapeutic, and technological nuances.
  • Supports strategic planning to mitigate risk and capitalize on emerging tariffs, regulatory changes, and competitive shifts.
  • Offers a reliable evidence base for partnership, clinical development, and market access decisions in a changing therapeutic arena.

Conclusion

Comprehensive market coverage and strategic analysis empower decision-makers to address ongoing change in neutropenia care. This report provides the clarity, segment detail, and industry foresight needed to excel in a dynamic and evolving market landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neutropenia Treatment Market, by Treatment Type
8.1. Introduction
8.2. Filgrastim
8.2.1. 300 mcg
8.2.2. 480 mcg
8.2.3. 600 mcg
8.3. Lenograstim
8.3.1. 3 mg
8.3.2. 5 mg
8.4. Pegfilgrastim
8.4.1. 6 mg
9. Neutropenia Treatment Market, by Therapy Class
9.1. Introduction
9.2. Biosimilar
9.3. Originator
10. Neutropenia Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravenous Injection
10.3. Subcutaneous Injection
11. Neutropenia Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Neutropenia Treatment Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.4. Home Care
12.5. Hospitals
12.5.1. Private
12.5.2. Public
13. Neutropenia Treatment Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Neutropenia Treatment Market, by Severity
14.1. Introduction
14.2. Mild
14.3. Moderate
14.4. Severe
15. Americas Neutropenia Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Neutropenia Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Neutropenia Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Amgen Inc.
18.3.2. Sandoz International GmbH
18.3.3. Pfizer Inc.
18.3.4. Teva Pharmaceutical Industries Ltd.
18.3.5. Viatris Inc.
18.3.6. Coherus BioSciences, Inc.
18.3.7. Fresenius Kabi AG
18.3.8. Intas Pharmaceuticals Ltd.
18.3.9. Biocon Limited
18.3.10. Celltrion, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. NEUTROPENIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. NEUTROPENIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. NEUTROPENIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEUTROPENIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 79. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 81. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 82. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 83. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 84. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 92. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 94. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 95. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 96. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 158. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 160. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 161. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 162. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 166. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 167. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 171. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 173. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 174. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 175. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 197. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 199. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 200. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 201. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 202. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 205. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 212. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 213. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 214. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 219. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 262. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 264. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 265. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 266. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 270. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 271. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 274. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 288. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 290. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 291. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 292. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 293. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 296. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 301. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 303. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 304. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 305. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 309. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 310. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 314. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neutropenia Treatment market report include:
  • Amgen Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Biocon Limited
  • Celltrion, Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.24 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chemotherapy Induced Neutropenia Market by Product Type, Therapy, Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast to 2030 - Product Image

Chemotherapy Induced Neutropenia Market by Product Type, Therapy, Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Neutropenia Biologic Drug Treatment Market Report 2025 - Product Image

Neutropenia Biologic Drug Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Febrile Neutropenia Market - Product Image

Febrile Neutropenia Market

  • Report
  • 250 Pages
  • Global
From
Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From

About the Neutropenia Drug Market

Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition. The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.